Literature DB >> 21472332

Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease.

Yugang Wang1, Min Shi, Hongyi Fu, Hui Xu, Jue Wei, Ting Wang, Xinmin Wang.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a common liver disease associated with an increased risk of type 2 diabetes and cardiovascular disease. Many factors may contribute to NAFLD development and progression, but the exact mechanisms are still not fully understood. In this study, Sprague-Dawley rats were fed either a standard diet (control group), a high-fat diet for 8 weeks (the HFD-8 group) or a high-fat diet for 16 weeks (the HFD-16 group). The HFD animals showed high levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and insulin resistance index (Homa-IR). Mild and severe steatosis was found in both the HFD-8 and HFD-16 groups, respectively. Compared with the controls, mRNA levels of mTOR, S6K1, IL-1α, IL-6 and TNFα were significantly increased in the HFD-8 and HFD-16 groups. IRS-1 mRNA was significantly increased in the HFD-8 group, but not in the HFD-16 group. The protein levels of mTOR, pmTOR(Ser2448), S6K1, pIRS-1(Ser307), IL-1α and IL-6 were significantly increased in the HFD-8 and HFD-16 groups. The protein levels of pmTOR(Ser2448) and IL-1α were significantly higher in the HFD-16 group compared to those in the HFD-8 group. However, the protein expression level of mTOR did not differ significantly between the HFD-8 and HFD-16 groups. The pIRS-1(Tyr102) level was significantly lower in both the HFD-8 and HFD-16 groups when compared to that in the control group, and the pIRS-1(Tyr102) level was significantly lower in the HFD-16 group compared to that of the HFD-8 group. pmTOR(Ser2448) was positively correlated with the TNFα mRNA level, and pIRS-1(Ser307) was positively correlated with pmTOR(Ser2448), TNFα, S6K1 and mTOR. pIRS-1(Tyr102) was negatively correlated with pmTOR(Ser2448), TNFα, S6K1 and mTOR. These data indicate that mTOR contributes to insulin resistance and chronic liver inflammation, and may play an important role in the development and progression of NAFLD.

Entities:  

Year:  2010        PMID: 21472332     DOI: 10.3892/mmr.2010.365

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  13 in total

1.  mTOR activation protects liver from ischemia/reperfusion-induced injury through NF-κB pathway.

Authors:  Ziru Li; Jing Zhang; Michael Mulholland; Weizhen Zhang
Journal:  FASEB J       Date:  2017-03-29       Impact factor: 5.191

Review 2.  Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives.

Authors:  Christina-Maria Flessa; Ioannis Kyrou; Narjes Nasiri-Ansari; Gregory Kaltsas; Athanasios G Papavassiliou; Eva Kassi; Harpal S Randeva
Journal:  Curr Obes Rep       Date:  2021-03-22

3.  Modified Linggui Zhugan Decoction () Ameliorates Glycolipid Metabolism and Inflammation via PI3K-Akt/mTOR-S6K1/AMPK-PGC-1 α Signaling Pathways in Obese Type 2 Diabetic Rats.

Authors:  Jia-Pan Sun; Lin Shi; Fang Wang; Jian Qin; Bin Ke
Journal:  Chin J Integr Med       Date:  2020-11-19       Impact factor: 1.978

Review 4.  Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis.

Authors:  Gwang-woong Go
Journal:  Nutrients       Date:  2015-06-03       Impact factor: 5.717

Review 5.  An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease.

Authors:  Aurèle Besse-Patin; Jennifer L Estall
Journal:  Int J Cell Biol       Date:  2014-02-12

Review 6.  Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease.

Authors:  Cong Liu; Jia-Zhi Liao; Pei-Yuan Li
Journal:  World J Gastroenterol       Date:  2017-03-21       Impact factor: 5.742

Review 7.  Lipid metabolism, inflammation, and foam cell formation in health and metabolic disorders: targeting mTORC1.

Authors:  So Yeong Cheon; KyoungJoo Cho
Journal:  J Mol Med (Berl)       Date:  2021-07-26       Impact factor: 4.599

8.  A Systems Biology Approach to Deciphering the Etiology of Steatosis Employing Patient-Derived Dermal Fibroblasts and iPS Cells.

Authors:  Justyna Jozefczuk; Karl Kashofer; Ramesh Ummanni; Frauke Henjes; Samrina Rehman; Suzanne Geenen; Wasco Wruck; Christian Regenbrecht; Andriani Daskalaki; Christoph Wierling; Paola Turano; Ivano Bertini; Ulrike Korf; Kurt Zatloukal; Hans V Westerhoff; Hans Lehrach; James Adjaye
Journal:  Front Physiol       Date:  2012-09-03       Impact factor: 4.566

9.  Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease.

Authors:  Dan-Qin Sun; Wen-Yue Liu; Sheng-Jie Wu; Gui-Qi Zhu; Martin Braddock; Dong-Chu Zhang; Ke-Qing Shi; Dan Song; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2016-02-02

10.  LXRɑ participates in the mTOR/S6K1/SREBP-1c signaling pathway during sodium palmitate-induced lipogenesis in HepG2 cells.

Authors:  Huihong Yu; Wei Shen; Youping Zhou; Shengjie Yu; Can Cai; Li Zhong
Journal:  Nutr Metab (Lond)       Date:  2018-05-02       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.